Impact of pregabalin treatment on synaptic plasticity and glial reactivity during the course of experimental autoimmune encephalomyelitis

Brain and Behavior

Volumn 4, Issue 6, 2014, Pages 925-935

  Silva, Gleidy A A ^a   Pradella, Fernando ^a   Moraes, Adriel ^a   Farias, Alessandro ^a   dos Santos, Leonilda M B ^a   de Oliveira, Alexandre L R ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Experimental autoimmune encephalomyelitis; Pregabalin; Spinal motoneurons; Synapse

Indexed keywords

CALCIUM BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 10; INTERLEUKIN 27; INTERLEUKIN 6; PLACEBO; PREGABALIN; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; 4 AMINOBUTYRIC ACID; ACTIN BINDING PROTEIN; AIF1 PROTEIN, RAT; CYTOKINE; NEUROPROTECTIVE AGENT; SYP PROTEIN, RAT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; GLIAL REACTIVITY; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVOUS SYSTEM FUNCTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNAPSE; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GLIA; GLIOSIS; LEWIS RAT; METABOLISM; MOTONEURON; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SPINAL CORD;

ANIMALS; CALCIUM-BINDING PROTEINS; CYTOKINES; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; IMMUNOHISTOCHEMISTRY; MICROFILAMENT PROTEINS; MOTOR ACTIVITY; MOTOR NEURONS; NEUROGLIA; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; PREGABALIN; RATS, INBRED LEW; REAL-TIME POLYMERASE CHAIN REACTION; SPINAL CORD; SYNAPSES; SYNAPTOPHYSIN;

EID: 84911434558     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.276     Document Type: Article

References (47)

1. Achiron, A., and M. Gurevich. 2006. Peripheral blood gene expression signature mirrors central nervous system disease: the model of multiple sclerosis. Autoimmun. Rev. 5:517-522.
2. Ahlgren, C., A. Oden, and J. Lycke. 2012. A nationwide survey of the prevalence of multiple sclerosis in immigrant populations of Sweden. Mult. Scler. 18:1099-1107.
3. Aranami, T., and T. Yamamura. 2008. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int. 57:115-120.
4. Balashov, K. E., D. R. Smith, S. J. Khoury, D. A. Hafler, and H. L. Weiner. 1997. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA 94:599-603.
5. Bentzen, J., E. M. Flachs, E. Stenager, H. Bronnum-Hansen, and N. Koch-Henriksen. 2010. Prevalence of multiple sclerosis in Denmark 1950-2005. Mult. Scler. 16:520-525.
6. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238.
7. Blanchette, F., and O. Neuhaus. 2008. Glatiramer acetate: evidence for a dual mechanism of action. J. Neurol. 255(Suppl 1):26-36.
8. Bluestein, K. T., D. Pitt, S. Sammet, C. R. Zachariah, U. Nagaraj, M. V. Knopp, et al. 2012. Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation. Magn. Reson. Imaging 30:907-915.
9. Brocke, S., L. Quigley, H. F. McFarland, and L. Steinman. 1996. Isolation and characterization of autoreactive T Cells in experimental autoimmune encephalomyelitis of the mouse. Methods 9:458-462.
10. Butterfield, R. J., E. P. Blankenhorn, R. J. Roper, J. F. Zachary, R. W. Doerge, J. Sudweeks, et al. 1999. Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/nonrelapsing EAE are immunogenetically distinct. J. Immunol. 162:3096-3102.
11. Cadavid, D., S. Jurgensen, and S. Lee. 2013. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS ONE 8:e53297.
12. Clerico, M., F. Faggiano, J. Palace, G. Rice, M. Tintore, and L. Durelli. 2008. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst. Rev. (2):CD005278.
13. Correale, J. 2013. If I had clinically isolated syndrome with magnetic resonance imaging diagnostic of multiple sclerosis, I would take vitamin D 10, 000 IU daily: yes. Mult. Scler. 19:137-139.
14. Cullheim, S., W. Wallquist, H. Hammarberg, H. Linda, F. Piehl, T. Carlstedt, et al. 2002. Properties of motoneurons underlying their regenerative capacity after axon lesions in the ventral funiculus or at the surface of the spinal cord. Brain Res. Brain Res. Rev. 40:309-316.
15. Dhib-Jalbut, S. 2003. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol. Ther. 98:245-255.
16. Eutamene, H., A. M. Coelho, V. Theodorou, M. Toulouse, M. Chovet, A. Doherty, et al. 2000. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J. Pharmacol. Exp. Ther. 295:162-167.
17. Fitzgerald, D. C., B. Ciric, T. Touil, H. Harle, J. Grammatikopolou, J. Das Sarma, et al. 2007. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 179:3268-3275.
18. Freria, C. M., R. G. Zanon, L. M. Santos, and A. L. Oliveira. 2010. Major histocompatibility complex class I expression and glial reaction influence spinal motoneuron synaptic plasticity during the course of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 518:990-1007.
19. Galicia, G., A. Kasran, C. Uyttenhove, K. de Swert, J. van Snick, and J. L. Ceuppens. 2009. ICOS deficiency results in exacerbated IL-17 mediated experimental autoimmune encephalomyelitis. J. Clin. Immunol. 29:426-433.
20. Gold, R., R. A. Linker, and A. Chan. 2007. Termination of inflammation in the nervous system. Rev. Neurol. (Paris) 163:672-676.
21. Goodin, D. S. 2013. The use of interferon Beta and glatiramer acetate in multiple sclerosis. Semin. Neurol. 33:13-25.
22. Ha, K. Y., Y. H. Kim, K. W. Rhyu, and S. E. Kwon. 2008. Pregabalin as a neuroprotector after spinal cord injury in rats. Eur. Spine J. 17:864-872.
23. Ha, K. Y., E. Carragee, I. Cheng, S. E. Kwon, and Y. H. Kim. 2011. Pregabalin as a neuroprotector after spinal cord injury in rats: biochemical analysis and effect on glial cells. J. Korean Med. Sci. 26:404-411.
24. Hammarberg, H., O. Lidman, C. Lundberg, S. Y. Eltayeb, A. W. Gielen, S. Muhallab, et al. 2000. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J. Neurosci. 20:5283-5291.
25. Hickey, W. F. 1999. The pathology of multiple sclerosis: a historical perspective. J. Neuroimmunol. 98:37-44.
26. Jalilian, B., H. B. Einarsson, and T. Vorup-Jensen. 2012. Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system? Int. J. Mol. Sci. 13:14579-14605.
27. Joshi, I., and C. P. Taylor. 2006. Pregabalin action at a model synapse: binding to presynaptic calcium channel alpha2-delta subunit reduces neurotransmission in mice. Eur. J. Pharmacol. 553:82-88.
28. Kaya, D., E. Idiman, and S. Ozakbas. 2012. Inflammatory demyelinating central nervous system diseases in childhood: clinical and paraclinical profiles in 133 patients. Autoimmune Dis. 2012:957802.
29. Korn, T., E. Bettelli, M. Oukka, and V. K. Kuchroo. 2009. IL-17 and Th17 Cells. Annu. Rev. Immunol. 27:485-517.
30. Kornek, B., M. K. Storch, R. Weissert, E. Wallstroem, A. Stefferl, T. Olsson, et al. 2000. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157:267-276.
31. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
32. Mackenzie, I. S., S. V. Morant, G. A. Bloomfield, T. M. Macdonald, and J. O'Riordan. 2014. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. J. Neurol. Neurosurg. Psychiatry 85:76-84.
33. Marques, K. B., L. M. Santos, and A. L. Oliveira. 2006. Spinal motoneuron synaptic plasticity during the course of an animal model of multiple sclerosis. Eur. J. Neurosci. 24:3053-3062.
34. Marques, K. B., J. M. Scorisa, R. Zanon, C. M. Freria, L. M. Santos, B. P. Damasceno, et al. 2009. The immunomodulator glatiramer acetate influences spinal motoneuron plasticity during the course of multiple sclerosis in an animal model. Braz. J. Med. Biol. Res. 42:179-188.
35. Murphy, A. C., S. J. Lalor, M. A. Lynch, and K. H. Mills. 2010. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav. Immun. 24:641-651.
36. Olsson, T., I. Dahlman, E. Wallstrom, R. Weissert, and F. Piehl. 2000. Genetics of rat neuroinflammation. J. Neuroimmunol. 107:191-200.
37. Pin, J. P., and R. Duvoisin. 1995. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34:1-26.
38. Pollmann, W., and W. Feneberg. 2008. Current management of pain associated with multiple sclerosis. CNS Drugs 22:291-324.
39. Rasouli, A., N. Bhatia, P. Dinh, K. Cahill, S. Suryadevara, and R. Gupta. 2009. Resection of glial scar following spinal cord injury. J. Orthop. Res. 27:931-936.
40. Scorisa, J. M., C. M. Freria, S. C. Victorio, R. Barbizan, R. G. Zanon, and A. L. Oliveira. 2011. Glatiramer acetate treatment increases stability of spinal synapses and down regulates MHC I during the course of EAE. Int. J. Biol. Sci. 7:1188-1202.
41. Seger, J., S. F. Zorzella-Pezavento, A. C. Pelizon, D. R. Martins, A. Domingues, and A. Sartori. 2010. Decreased production of TNF-alpha by lymph node cells indicates experimental autoimmune encephalomyelitis remission in Lewis rats. Mem. Inst. Oswaldo Cruz 105:263-268.
42. Sellner, J., J. Kraus, A. Awad, R. Milo, B. Hemmer, and O. Stuve. 2011. The increasing incidence and prevalence of female multiple sclerosis-a critical analysis of potential environmental factors. Autoimmun. Rev. 10:495-502.
43. Serada, S., M. Fujimoto, M. Mihara, N. Koike, Y. Ohsugi, S. Nomura, et al. 2008. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 105:9041-9046.
44. Silver, J., and J. H. Miller. 2004. Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5:146-156.
45. Solaro, C., and P. Tanganelli. 2009. Acute delirium in patients with multiple sclerosis treated with pregabalin. Clin. Neuropharmacol. 32:236-237.
46. Sternberger, N. H., L. A. Sternberger, M. W. Kies, and C. R. Shear. 1989. Cell surface endothelial proteins altered in experimental allergic encephalomyelitis. J. Neuroimmunol. 21:241-248.
47. Swanborg, R. H. 2001. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol. Rev. 184:129-135.